LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice.

@article{Park2018LJ1888AS,
  title={LJ-1888, a selective antagonist for the A3 adenosine receptor, ameliorates the development of atherosclerosis and hypercholesterolemia in apolipoprotein E knock-out mice.},
  author={Jong-Gil Park and Se-Jin Jeong and Jinha Yu and Gyudong Kim and Lak Shin Jeong and Goo Taeg Oh},
  journal={BMB reports},
  year={2018}
}
Cardiovascular diseases arising from atherosclerosis are the leading causes of mortality and morbidity worldwide. Lipid-lowering agents have been developed in order to treat hypercholesterolemia, a major risk factor for atherosclerosis. However, the prevalence of cardiovascular diseases is increasing, indicating a need to identify novel therapeutic targets… CONTINUE READING